These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 106453)

  • 1. [Antithrombin III (clinical aspects and methodology)].
    Abildgaard U
    Ric Clin Lab; 1978; 8 Suppl 2():90-7. PubMed ID: 106453
    [No Abstract]   [Full Text] [Related]  

  • 2. [Antithrombin III determinations in internal medicine and surgery].
    Schmitz-Huebner U
    Med Lab (Stuttg); 1980 Sep; 33(9):232-5. PubMed ID: 7442606
    [No Abstract]   [Full Text] [Related]  

  • 3. [Importance of the determination of thrombin-antithrombin-III complexes in hypercoagulability states].
    García Avello A; García Frade A; Sureda JL; Torrado MC
    Sangre (Barc); 1991 Apr; 36(2):163. PubMed ID: 1866654
    [No Abstract]   [Full Text] [Related]  

  • 4. Adaptation of synthetic peptide substrate-based assays on a discrete analyzer.
    Aiach M; Léon M; Michaud A; Capron L
    Semin Thromb Hemost; 1983 Jul; 9(3):206-16. PubMed ID: 6351255
    [No Abstract]   [Full Text] [Related]  

  • 5. [Significance of the amidolytic method in the typing of congenital antithrombin III deficiency].
    Losonczy H; Nagy I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):184-8. PubMed ID: 6177603
    [No Abstract]   [Full Text] [Related]  

  • 6. Antithrombin III, protein C, and protein S. Naturally occurring anticoagulant proteins.
    High KA
    Arch Pathol Lab Med; 1988 Jan; 112(1):28-36. PubMed ID: 2962557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antithrombin III: critical review of the methods used for its monitoring in thrombophilic states].
    Modiano A; Belisario A
    G Clin Med; 1981 Sep; 62(9):597-608. PubMed ID: 7033027
    [No Abstract]   [Full Text] [Related]  

  • 8. Heparin and antithrombin 3.
    Stein ZL
    Arch Surg; 1979 Aug; 114(8):980. PubMed ID: 464818
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-thrombin III levels in some Malaysian patients suspected of having acquired coagulation disorders.
    Tan SH; Doraisamy G; Noriah R; Lopez CG
    Singapore Med J; 1983 Feb; 24(1):33-6. PubMed ID: 6867763
    [No Abstract]   [Full Text] [Related]  

  • 10. Further investigations on antithrombin III in the plasmas of patients with the abnormality of antithrombin III Budapest.
    Sas G; Pepper DS; Cash JD
    Thromb Diath Haemorrh; 1975 Jun; 33(3):564-72. PubMed ID: 1154312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Antithrombin-III activity in clotting disorders in polytraumatized patients (author's transl)].
    Sefrin P; Brunswig D; Wenzel M
    Dtsch Med Wochenschr; 1982 Mar; 107(10):383-5. PubMed ID: 7060468
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of natural coagulation inhibitors in hemostasis.
    Brandt JT
    Clin Lab Med; 1984 Jun; 4(2):245-84. PubMed ID: 6094091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An antithrombin III assay based on factor Xa inhibition provides a more reliable test to identify congenital antithrombin III deficiency than an assay based on thrombin inhibition.
    Demers C; Henderson P; Blajchman MA; Wells MJ; Mitchell L; Johnston M; Ofosu FA; Fernandez-Rachubinski F; Andrew M; Hirsh J
    Thromb Haemost; 1993 Mar; 69(3):231-5. PubMed ID: 8470046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Blood clotting diagnosis with chromogenic substrates].
    Róka L; Rasche H
    Internist (Berl); 1980 Apr; 21(4):189-94. PubMed ID: 6998907
    [No Abstract]   [Full Text] [Related]  

  • 15. [Studies on plasma hypercoagulability. 1. Heparin resistance in various diseases and its relation to coagulation factors, anticoagulant therapy, platelet and heparin co-factor].
    Satake K
    Naika Hokan; 1969 Apr; 16(4):127-38. PubMed ID: 5816626
    [No Abstract]   [Full Text] [Related]  

  • 16. Heparin cofactor deficiency and instability as reflected by the 24-hour heparin clot inhibition test.
    Koszewski BJ; Powell LW; Vahabzadeh H
    Vasc Dis; 1968 Sep; 5(3):152-64. PubMed ID: 5676640
    [No Abstract]   [Full Text] [Related]  

  • 17. [From clinical tests to etiology: analysis of clinical features. Coagulation disorders].
    Sakuragawa N
    Rinsho Byori; 1987 Dec; Spec No 75():135-44. PubMed ID: 3448279
    [No Abstract]   [Full Text] [Related]  

  • 18. Thrombin-based antithrombin assays show overestimation of antithrombin III activity in patients on heparin therapy due to heparin cofactor II influence.
    Bohner J; von Pape KW; Blaurock M
    Thromb Haemost; 1994 Mar; 71(3):280-3. PubMed ID: 8029789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Round table on the use of chromogenic substrates in hemostasiologic diagnosis].
    Vogel G
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):189-200. PubMed ID: 6177604
    [No Abstract]   [Full Text] [Related]  

  • 20. [Comparative studies on the determination of abnormal antithrombin III activity].
    Nagy I; Losonczy H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):180-3. PubMed ID: 6177602
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.